NICE Guideline for Pneumonia: Diagnosis and Management

Overview

  • This guideline provides a comprehensive approach to diagnosing, assessing, and treating pneumonia, including:
    • Community-acquired pneumonia (CAP)
    • Hospital-acquired pneumonia (HAP)
    • Bacterial pneumonia resulting from COVID-19)
  • Age groups included: Babies (over 1 month), children, young people, and adults.
  • Focus on optimizing antibiotic use to combat antibiotic resistance.
  • Exclusions: Ventilator-associated pneumonia, COVID-19 pneumonia.

Target Audience

  • Healthcare professionals
  • Patients with suspected or confirmed pneumonia, and their families/carers.

Key Sections of the Guideline

  1. Recommendations
  2. First contact with NHS services (remote/in-person)
  3. Assessing community-acquired pneumonia (CAP)
  4. Assessment tools for hospital-acquired pneumonia (HAP)
  5. Investigations in hospital
  6. Starting and reviewing antibiotics
  7. Details about antibiotic treatment for both CAP and HAP
  8. Corticosteroid treatment in hospital
  9. Non-invasive respiratory support
  10. Patient information about pneumonia treatment and recovery
  11. Reassessing the condition
  12. Follow-up chest X-rays

New and Updated Recommendations

  • New recommendations are marked [2025].
  • Comments on existing recommendations from the 2014 guideline may be proposed for deletion.
  • Some wording changes made for clarity. Consult evidence reviews for detailed discussions.

Risk Assessment Tools

  • CRB65 for CAP
    • Score parameters:
    • Confusion (1 point)
    • Respiratory rate ≥30 (1 point)
    • Low blood pressure (systolic <90 mmHg or diastolic ≤60 mmHg; 1 point)
    • Age ≥65 (1 point)
  • Stratification:
    • 0: Low risk (mortality <1%)
    • 1-2: Intermediate risk (mortality 1-10%)
    • 3-4: High risk (mortality >10%)
  • CURB65 for HAP
    • Similar scoring system for hospitalized adult patients.

Management Recommendations

  1. Management of CAP

    • Initiate antibiotics promptly after diagnosis (ideally within 4 hours).
    • Review antibiotic effectiveness by 48 hours and adjust if necessary.
    • For adults: Start with oral antibiotics if feasible.
    • Stop antibiotics after 5 days if not indicated otherwise (check clinical stability).
    • For children: A 3-day course is often sufficient if symptoms are mild.

  2. Management of HAP

    • Use appropriate antibiotics based on severity of symptoms and risk profile.
    • Review after 5 days: Stop if clinically stable.

Corticosteroid Treatment

  • Recommended for high-severity CAP cases in hospital settings alongside antibiotics.
  • Suggested starting corticosteroid: IV hydrocortisone or alternatives if not suitable.

Non-Invasive Respiratory Support

  • Consider high-flow nasal oxygen or CPAP for pneumonia patients with respiratory failure, based on patient condition.

Advice for Patients

  • Expectations for Recovery
    • Adults:
    • Fever resolution: ~1 week
    • Cough and breathlessness: ~6 weeks
    • Children: symptom improvement may take longer but typically resolve in about 3-4 days without additional intervention.

Reassessment Guidelines

  • Conduct if symptoms do not improve significantly or worsen.
  • Use biomarkers (CRP, Procalcitonin) to assess treatment effectiveness after a few days.

Follow-Up Imaging

  • Do not routinely require follow-up chest X-rays after hospital discharge for pneumonia unless specific risk factors are present is essential.

Research Recommendations

  1. Predictive Tools: For children to improve accuracy in referrals.
  2. Corticosteroid Efficacy: Investigate optimal treatment parameters.
  3. Assessment Tools for HAP: Research on clinical effectiveness needed.

Context of Guidelines

  • Updated from CG191 (2014) and incorporates findings from NG138 (community-acquired) and NG139 (hospital-acquired) guidelines.
  • Pneumonia remains a significant cause of morbidity and mortality in the UK, necessitating clear clinical guidelines for effective management.

Conclusion

  • This updated guideline centers on reliable diagnosis, effective antibiotic management, optimized treatment pathways for different patient populations, and research directions to enhance pneumonia care.